What Is Tirzepatide?
Tirzepatide is a synthetic peptide compound developed by Eli Lilly that acts on two distinct hormone receptor systems simultaneously. It is approved in the European Union under the brand name Mounjaro for the treatment of type 2 diabetes, and has received approval in multiple jurisdictions for chronic weight management under the name Zepbound. In Ireland, it is regulated by the Health Products Regulatory Authority (HPRA) and is available by prescription through the standard clinical pathway.
Structurally, tirzepatide is a 39-amino acid peptide administered as a once-weekly subcutaneous injection. What distinguishes it from earlier peptide-based treatments is its dual-receptor activity — a design feature that places it in a different category from single-target compounds like semaglutide. This dual mechanism is the primary reason tirzepatide has attracted significant attention from the metabolic research community since its clinical trials began.
For researchers and health science professionals in Ireland tracking the peptide landscape, tirzepatide represents a meaningful step in the evolution of incretin-based therapy. Its development also provides context for understanding the next generation of compounds, including retatrutide, a triple-agonist currently in clinical evaluation.
How It Works — The Mechanism
To understand tirzepatide's mechanism, it helps to understand the two receptor systems it engages: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Both are part of the incretin hormone system — a network of gut-derived signals that modulate insulin secretion in response to food intake.
GLP-1 receptor agonism is already well characterised through compounds like semaglutide and liraglutide. When a GLP-1 receptor agonist binds to its target, it stimulates insulin release from pancreatic beta cells in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system signalling. The result is reduced postprandial blood glucose and, at sustained doses, meaningful reductions in body weight.
GIP receptor agonism adds a separate but complementary layer. GIP is typically released from the small intestine in response to fat and carbohydrate ingestion. In healthy metabolic states, GIP enhances insulin secretion alongside GLP-1. Critically, GIP also appears to act on adipose tissue and may influence energy partitioning — how the body stores and utilises fat. There is also evidence that GIP receptor activation can augment the weight-lowering effects of GLP-1 agonism, though the precise interaction between the two pathways is still being characterised in ongoing research.
Tirzepatide is engineered as a single molecule that activates both receptors, with a pharmacological profile that prioritises GIP agonism alongside balanced GLP-1 activity. This dual engagement is referred to as twincretin activity. The hypothesis driving its development was that combining both pathways would deliver superior glycaemic control and greater weight reduction than either pathway alone — a hypothesis that the clinical trial data has, to a notable degree, supported.
What Does the Research Say?
The clinical evidence base for tirzepatide is among the most extensive assembled for any metabolic compound to date. Two major trial programmes dominate the published literature: SURPASS (focused on type 2 diabetes management) and SURMOUNT (focused on weight reduction in people with obesity).
The SURPASS programme comprised five phase 3 trials enrolling adult humans with type 2 diabetes. Across these trials, tirzepatide at doses of 5 mg, 10 mg, and 15 mg demonstrated statistically significant reductions in HbA1c — a standard marker of long-term blood glucose control. In SURPASS-2, a head-to-head comparison with semaglutide 1 mg, tirzepatide at all three doses produced greater HbA1c reductions. The 15 mg dose achieved a mean HbA1c reduction of approximately 2.46 percentage points versus 1.86 for semaglutide 1 mg. These are human clinical trial findings across thousands of participants, representing a high level of evidence by conventional standards.
The SURMOUNT programme examined tirzepatide for weight management in adults without diabetes but with obesity or overweight plus at least one weight-related complication. SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 participants over 72 weeks. At the 15 mg dose, participants achieved a mean body weight reduction of approximately 22.5% — the highest figure recorded for any approved pharmacological intervention for weight management at the time of publication. The 5 mg and 10 mg doses produced mean reductions of around 15% and 19.5% respectively. These findings are from a randomised, double-blind, placebo-controlled trial, which represents robust methodology.
Researchers should note several important limitations and caveats in the existing literature. First, most SURMOUNT data reflects outcomes at 72 weeks — long-term data beyond this period is still accumulating. Second, weight regain following discontinuation has been observed, consistent with patterns seen across GLP-1 class compounds. Third, the majority of participants in these trials were from North American and European populations, and subgroup analyses by ethnicity or specific comorbidity profile are ongoing. Adverse events, primarily gastrointestinal in nature (nausea, vomiting, diarrhoea), were common, particularly during dose escalation, and led to trial discontinuation in a meaningful proportion of participants.
On insulin sensitivity specifically, tirzepatide has demonstrated improvements in HOMA-IR (a standard proxy measure of insulin resistance) and fasting insulin levels across multiple trials. Whether these improvements are driven primarily by weight loss itself or represent an independent metabolic effect of GIP receptor agonism remains an active area of investigation. Some researchers argue the GIP component provides additive insulin-sensitising effects beyond what weight reduction alone would predict — but this remains a hypothesis requiring further controlled study.
Context for Irish Researchers
In Ireland, tirzepatide (Mounjaro) has been approved by the European Medicines Agency (EMA) and is regulated domestically by the HPRA. It is a prescription-only medicine under Irish law, classified for use in adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Prescribing decisions in Ireland follow HPRA and HSE guidelines, and off-label use falls under the clinical responsibility of the prescribing physician.
For researchers in Ireland tracking the broader peptide research landscape, tirzepatide's regulatory trajectory is instructive. The speed of its approval pathway — from phase 3 data publication to EMA authorisation — reflects the strength of the clinical evidence base assembled through the SURPASS and SURMOUNT programmes. Compounds with robust, large-scale human trial data move through regulatory review more efficiently than those relying primarily on preclinical or animal data.
The Irish market context is also relevant. Rates of obesity and type 2 diabetes in Ireland have risen steadily over the past two decades, tracking broader European trends. The HSE's chronic disease management frameworks have increasingly incorporated structured pathways for GLP-1 class therapies. Tirzepatide's positioning as a dual-agonist with superior efficacy data versus earlier generation compounds means it is likely to feature prominently in Irish clinical guidelines reviews over the coming years.
For those following the research pipeline beyond tirzepatide, retatrutide — a triple-agonist targeting GLP-1, GIP, and glucagon receptors — is currently in phase 3 development. Early phase 2 data published in 2023 suggested even greater weight reduction percentages than tirzepatide, though this remains an experimental compound without regulatory approval at the time of writing. Tirzepatide's mechanistic framework is the immediate precursor to understanding where triple-agonist research is headed.
Key Takeaways
- Tirzepatide is a dual GLP-1/GIP receptor agonist — its simultaneous activation of two incretin pathways distinguishes it from earlier single-target compounds.
- It is approved in Ireland and the EU as Mounjaro (type 2 diabetes) and is regulated by the HPRA as a prescription-only medicine.
- SURMOUNT-1 trial data (human, randomised controlled, n=2,539) demonstrated up to 22.5% mean body weight reduction at 72 weeks — the strongest published figure for any approved weight management medication to date.
- SURPASS-2 head-to-head data showed superior HbA1c reduction versus semaglutide 1 mg across all three tirzepatide doses in adults with type 2 diabetes.
- Evidence for insulin sensitisation beyond weight-loss effects exists but remains under active investigation — causal attribution between GIP receptor agonism and insulin sensitivity improvements is not yet fully established.
- Gastrointestinal adverse events are common, particularly during dose escalation, and long-term post-discontinuation data is still accumulating.
- Tirzepatide provides the mechanistic and clinical foundation for understanding next-generation compounds such as retatrutide (triple agonist, currently in phase 3 trials).
- All research on tirzepatide discussed here is drawn from regulated human clinical trials — any application beyond approved clinical use requires appropriate regulatory and ethical oversight.
For research tools, protocol guides, and an updated index of peptide compounds currently in clinical development, visit irishpeptides.ie/free-tools.